Myers Squibb (NYSE:BMY) shares inched up on Friday after six consecutive sessions of fall. The stock was up 2.2% at $44.24.

Bristol-Myers Squibb remains a compelling Buy despite the market's over-reaction to the industry and macro headwinds. Learn ...

Myers Squibb (BMY) is a contrarian value play with a 5.39% dividend yield, strong growth strategy, and long-term potential.

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 4.2% in the afternoon session after the company ...

Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs ...

Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a ...

Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling ...

Shares of Bristol Myers Squibb Co. BMY slid 5.81% to $43.31 Thursday, on what proved to be an all-around dismal trading ...

Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...